ALLMedicine™ Radiation Necrosis Center

Jan 27th, 2023 - Differentiating brain metastasis progression from radiation effects or radiation necrosis (RN) remains challenging. Golden-angle radial sparse parallel (GRASP) dynamic contrast-enhanced MRI provides high spatial and temporal resolution to analyze ...

Jan 24th, 2023 - Stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICI) are highly effective treatments for brain metastases, particularly when these therapies are administered concurrently. However, there are limited data reporting the risk of rad...

Jan 19th, 2023 - The incidence of radionecrosis (RN) after stereotactic radiosurgery (SRS) to brain metastases is increasing. An overlap in the conventional MRI appearances of RN and tumour recurrence (TR) is diagnostically challenging. Delayed contrast MRI compar...

Jan 13th, 2023 - Cerebral radiation necrosis is a complication of radiation therapy that can be seen months to years following radiation treatment. Differentiating radiation necrosis from tumor progression on standard magnetic resonance imaging (MRI) is often diff...

Jan 12th, 2023 - Postradiation treatment necrosis is one of the most serious late sequelae and appears within 6 months. The magnetic resonance spectroscopy imaging (MRSI) has been used for the detection of brain tumors. The study aimed to determine the radiologica...

Jan 9th, 2023 - PRIMARY OBJECTIVE: I. To ascertain if the composite endpoint of cumulative treatment failure, defined by time to either local failure or symptomatic radiation brain necrosis of the largest brain metastasis (target lesion), is increased with fracti...

Jan 6th, 2023 - PRIMARY OBJECTIVE: I. To determine for patients with brain metastases meeting the inclusion criteria, whether there is an increase in the time to a composite endpoint of adverse outcomes including the first occurrence of either: local recurrence, ...

Jan 3rd, 2023 - GammaTile therapy results in improved clinical outcomes; however the data is a single site experience with a limited number of subjects, only 12 of which were patients with metastatic brain tumors. The primary objective of this randomized, control...

Dec 30th, 2022 - This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic radiosurgery in patients with melanoma brain metastases (MBM). We hypothesize that the addit...

Dec 12th, 2022 - Primary Objective To evaluate 6 month in-brain local control utilizing pre-operative stereotactic radiosurgery followed by surgical resection for brain metastases. Secondary Objectives Overall survival Distant in-brain progression Rate of leptomen...

Feb 23rd, 2022 - An abundance of riches in the form of new data for HER2-targeted agents continues to drive progress for patients with metastatic breast cancer. Efforts to address disease have resulted in the repurposing and movement of established agents in lines...

Nov 16th, 2021 - John V. Heymach, MD, PhD: We have some new studies coming out at the ESMO [European Society for Medical Oncology] 2021 Meeting and other meetings here. We had a study of bevacizumab [Avastin] and erlotinib [Tarceva], the BEVERLY study. Vamsi, what...

Oct 6th, 2021 - Tanios Bekaii-Saab, MD The treatment landscape of hepatocellular carcinoma (HCC) continues to expand, with some of the biggest approvals yet occurring in the past year, including the multikinase inhibitor regorafenib (Stivarga) and the PD-1 antib...

Oct 6th, 2021 - Arnold B. Etame, MD, PhD Neurological Surgeon and Scientist Moffitt Cancer Center, Tampa, FL Awake craniotomies are traditionally reserved for, but not limited to, tumors involving the primary motor (Figure 1) and speech (Figure 2) area...

May 14th, 2021 - Stereotactic radiosurgery (SRS) for brainstem metastases (BSM) appears to be safe and effective, and comparable to SRS for non-brainstem brain metastases (BM), according to researchers. Their systematic review and meta-analysis of retrospective st...